Bliss GVS Pharma Limited (BLISSGVS.BO)
INR 116.45
(-1.48%)
INR 116.45
(-1.48%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 3.69 Billion INR | -23.1% |
| 2022 | 3.46 Billion INR | -0.24% |
| 2021 | 3.46 Billion INR | 45.18% |
| 2020 | 2.38 Billion INR | -1.23% |
| 2019 | 2.41 Billion INR | -11.76% |
| 2018 | 2.74 Billion INR | 61.66% |
| 2017 | 1.69 Billion INR | -8.92% |
| 2016 | 1.86 Billion INR | -35.47% |
| 2015 | 2.88 Billion INR | 25.69% |
| 2014 | 2.29 Billion INR | 31.94% |
| 2013 | 1.74 Billion INR | -9.98% |
| 2012 | 1.93 Billion INR | 76.38% |
| 2011 | 1.09 Billion INR | 19.85% |
| 2010 | 914.43 Million INR | 16.78% |
| 2009 | 783.02 Million INR | 24.06% |
| 2008 | 631.15 Million INR | 9.19% |
| 2007 | 578.01 Million INR | 116.64% |
| 2006 | 266.8 Million INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 651.15 Million INR | -8.68% |
| 2024 Q2 | 1.02 Billion INR | 4.84% |
| 2023 Q2 | 1.12 Billion INR | 49.33% |
| 2023 Q1 | 750.95 Million INR | 4.83% |
| 2023 Q4 | 713.01 Million INR | -27.41% |
| 2023 Q3 | 982.31 Million INR | -12.4% |
| 2023 FY | 2.66 Billion INR | -23.1% |
| 2022 Q2 | 766.54 Million INR | -18.0% |
| 2022 Q4 | 716.33 Million INR | -31.34% |
| 2022 Q3 | 1.04 Billion INR | 36.1% |
| 2022 Q1 | 934.86 Million INR | 32.57% |
| 2022 FY | 3.46 Billion INR | -0.24% |
| 2021 FY | 3.46 Billion INR | 45.18% |
| 2021 Q2 | 900.29 Million INR | 10.62% |
| 2021 Q1 | 813.85 Million INR | 72.67% |
| 2021 Q4 | 705.19 Million INR | -32.85% |
| 2021 Q3 | 1.05 Billion INR | 16.64% |
| 2020 Q3 | 721.76 Million INR | 45.52% |
| 2020 Q2 | 495.98 Million INR | -1.03% |
| 2020 Q4 | 471.34 Million INR | -34.7% |
| 2020 Q1 | 501.13 Million INR | 19.76% |
| 2020 FY | 2.38 Billion INR | -1.23% |
| 2019 Q1 | 794.87 Million INR | 34.61% |
| 2019 Q2 | 542.94 Million INR | -31.69% |
| 2019 Q3 | 663.1 Million INR | 22.13% |
| 2019 Q4 | 418.44 Million INR | -36.9% |
| 2019 FY | 2.41 Billion INR | -11.76% |
| 2018 Q2 | 719.7 Million INR | 1.1% |
| 2018 Q1 | 711.89 Million INR | -21.94% |
| 2018 FY | 2.74 Billion INR | 61.66% |
| 2018 Q4 | 590.49 Million INR | -19.45% |
| 2018 Q3 | 733.08 Million INR | 1.86% |
| 2017 Q1 | 1.11 Billion INR | -31.44% |
| 2017 FY | 1.69 Billion INR | -8.92% |
| 2017 Q4 | 912.02 Million INR | -21.89% |
| 2017 Q3 | 1.16 Billion INR | 15.49% |
| 2017 Q2 | 1.01 Billion INR | -9.54% |
| 2016 Q4 | 1.63 Billion INR | 53.68% |
| 2016 Q3 | 1.06 Billion INR | 11.03% |
| 2016 Q2 | 955.43 Million INR | 27.52% |
| 2016 Q1 | 749.23 Million INR | 10.22% |
| 2016 FY | 1.86 Billion INR | -35.47% |
| 2015 Q3 | 1 Billion INR | 11.46% |
| 2015 Q1 | 613.8 Million INR | 0.0% |
| 2015 Q4 | 679.77 Million INR | -32.66% |
| 2015 FY | 2.88 Billion INR | 25.69% |
| 2015 Q2 | 905.7 Million INR | 47.56% |
| 2014 FY | 2.29 Billion INR | 31.94% |
| 2013 FY | 1.74 Billion INR | -9.98% |
| 2012 Q2 | 465.48 Million INR | 54.86% |
| 2012 Q4 | 761.69 Million INR | 90.24% |
| 2012 FY | 1.93 Billion INR | 76.38% |
| 2012 Q1 | 300.59 Million INR | 0.0% |
| 2012 Q3 | 400.37 Million INR | -13.99% |
| 2011 FY | 1.09 Billion INR | 19.85% |
| 2010 FY | 914.43 Million INR | 16.78% |
| 2009 FY | 783.02 Million INR | 24.06% |
| 2008 FY | 631.15 Million INR | 9.19% |
| 2007 FY | 578.01 Million INR | 116.64% |
| 2006 FY | 266.8 Million INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Bal Pharma Limited | 770.19 Million INR | -379.805% |
| Achyut Healthcare Limited | 4.86 Million INR | -75922.115% |
| Alkem Laboratories Limited | 52.29 Billion INR | 92.934% |
| Divi's Laboratories Limited | 32.44 Billion INR | 88.608% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 94.671% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | 70.277% |
| Krebs Biochemicals & Industries Limited | 192.72 Million INR | -1817.445% |
| Mankind Pharma Limited | 44.52 Billion INR | 91.7% |
| Medicamen Biotech Limited | 495.49 Million INR | -645.807% |
| Medico Remedies Limited | 262.14 Million INR | -1309.697% |
| Megasoft Limited | 342.07 Million INR | -980.312% |
| Procter & Gamble Health Limited | 5.78 Billion INR | 36.081% |
| Piramal Pharma Limited | 24.47 Billion INR | 84.899% |
| Sequent Scientific Limited | 2.97 Billion INR | -24.061% |
| Sigachi Industries Limited | 2 Billion INR | -84.561% |
| Ajanta Pharma Limited | 21.06 Billion INR | 82.456% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 98.57% |
| Brooks Laboratories Limited | 65.62 Million INR | -5531.568% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | 36.628% |
| Themis Medicare Limited | 1.5 Billion INR | -145.723% |
| Unichem Laboratories Limited | 4.86 Billion INR | 24.039% |
| Hester Biosciences Limited | 1.27 Billion INR | -190.145% |
| Venus Remedies Limited | 2.18 Billion INR | -69.315% |
| Indoco Remedies Limited | 6.04 Billion INR | 38.831% |
| Ind-Swift Limited | 2.17 Billion INR | -70.098% |
| Aarti Drugs Limited | 8.31 Billion INR | 55.563% |
| Alpa Laboratories Limited | 188.89 Million INR | -1856.343% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | 40.614% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 97.741% |
| Granules India Limited | 16.79 Billion INR | 78.002% |
| Gufic Biosciences Limited | 4.16 Billion INR | 11.332% |
| Hikal Limited | 3.14 Billion INR | -17.574% |
| RPG Life Sciences Limited | 2.48 Billion INR | -48.829% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | 10.376% |
| Windlas Biotech Limited | 1.33 Billion INR | -176.026% |
| ZIM Laboratories Limited | 1.26 Billion INR | -191.694% |
| Ind-Swift Laboratories Limited | 6.19 Billion INR | 40.342% |
| IOL Chemicals and Pharmaceuticals Limited | 4.58 Billion INR | 19.328% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 81.187% |
| Aurobindo Pharma Limited | 154.68 Billion INR | 97.611% |
| Bajaj HealthCare Limited | 1.47 Billion INR | -151.082% |
| Biofil Chemicals and Pharmaceuticals Limited | 14.57 Million INR | -25246.441% |
| Ipca Laboratories Limited | 29.8 Billion INR | 87.603% |
| Lasa Supergenerics Limited | 121.02 Million INR | -2953.322% |
| Laurus Labs Limited | 24.62 Billion INR | 84.99% |
| NATCO Pharma Limited | 25.73 Billion INR | 85.641% |
| Nectar Lifesciences Limited | 2.97 Billion INR | -24.339% |
| Shilpa Medicare Limited | 3.54 Billion INR | -4.189% |
| Solara Active Pharma Sciences Limited | 861.2 Million INR | -329.103% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 92.097% |
| Wanbury Limited | 1.73 Billion INR | -113.53% |
| Wockhardt Limited | 16.24 Billion INR | 77.245% |
| Strides Pharma Science Limited | 14.38 Billion INR | 74.316% |
| Suven Life Sciences Limited | -200.79 Million INR | 1940.384% |
| Amrutanjan Health Care Limited | 1.55 Billion INR | -137.415% |
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 86.201% |
| Eris Lifesciences Limited | 10.42 Billion INR | 64.558% |
| Lupin Limited | 123.71 Billion INR | 97.013% |
| Sun Pharma Advanced Research Company Limited | -602.4 Million INR | 713.446% |
| Syncom Formulations (India) Limited | 942.39 Million INR | -292.131% |
| Valiant Laboratories Limited | -60.66 Million INR | 6191.644% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 97.049% |
| FDC Limited | 8.33 Billion INR | 55.662% |
| J. B. Chemicals & Pharmaceuticals Limited | 22.69 Billion INR | 83.72% |
| Novartis India Limited | 1.32 Billion INR | -178.501% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | -466.272% |
| Neuland Laboratories Limited | 8.24 Billion INR | 55.195% |
| Morepen Laboratories Limited | 6.16 Billion INR | 40.022% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | -495.58% |
| Mangalam Drugs & Organics Limited | 703.6 Million INR | -425.214% |